LBLinda H. M. van de Burgwal

Linda H. M. van de Burgwal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linda H. M. van de Burgwal has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Australia's vaccine legacy: Time for a boost? Mapping an innovation system in a fragmented data environment

    by Linda H.M. van de Burgwal, Esther S. Pronker, Jennifer Herz

  • Open Access

    The potential of federated learning for public health purposes: a qualitative analysis of GDPR compliance, Europe, 2021

    by Natalie Lieftink, Carolina dos S Ribeiro, Mark Kroon, George B Haringhuizen, Albert Wong, Linda Hm van de Burgwal

    Background: The wide application of machine learning (ML) holds great potential to improve public health by supporting data analysis informing policy and practice. Its application, however, is often hampered by data fragmentation across organisations and strict regulation by the General Data Protection Regulation (GDPR). Federated learning (FL), as a decentralised approach to ML, has received considerable interest as a means to overcome the fragmentation of data, but it is yet unclear to which extent this approach complies with the GDPR. Aim: Our aim was to understand the potential data protection implications of the use of federated learning for public health purposes. Methods: Building upon semi-structured interviews (n = 14) and a panel discussion (n = 5) with key opinion leaders in Europe, including both FL and GDPR experts, we explored how GDPR principles would apply to the implementation of FL within public health. Results: Whereas this study found that FL offers substantial benefits such as data minimisation, storage limitation and effective mitigation of many of the privacy risks of sharing personal data, it also identified various challenges. These challenges mostly relate to the increased difficulty of checking data at the source and the limited understanding of potential adverse outcomes of the technology. Conclusion: Since FL is still in its early phase and under rapid development, it is expected that knowledge on its impracticalities will increase rapidly, potentially addressing remaining challenges. In the meantime, this study reflects on the potential of FL to align with data protection objectives and offers guidance on GDPR compliance.


  • Open Access

    Commercial Opportunity or Addressing Unmet Needs—Loop-Mediated Isothermal Amplification (LAMP) as the Future of Rapid Diagnostic Testing?

    by Jelle J. Feddema, Kenneth D. S. Fernald, Bart J. F. Keijser, Jasper Kieboom, Linda H. M. van de Burgwal

    Loop-Mediated Isothermal Amplification (LAMP) technology is emerging as a rapid pathogen testing method, potentially challenging the RT-PCR “gold standard”. Despite recent advancements, LAMP’s widespread adoption remains limited. This study provides a comprehensive market overview and assesses future growth prospects to aid stakeholders in strategic decision-making and policy formulation. Using a dataset of 1134 LAMP patent documents, we analyzed lifecycle and geographic distribution, applicant profiles, CPC code classifications, and patent claims. Additionally, we examined clinical developments from 21 curated clinical trials, focusing on trends, geographic engagement, sponsor types, and the conditions and pathogens investigated. Our analysis highlights LAMP’s potential as a promising rapid pathogen testing alternative, especially in resource-limited areas. It also reveals a gap between clinical research, which targets bacterial and parasitic diseases like malaria, leishmaniasis, and tuberculosis, and basic research and commercial efforts that prioritize viral diseases such as SARS-CoV-2 and influenza. European stakeholders emphasize the societal impact of addressing unmet needs in resource-limited areas, while American and Asian organizations focus more on research, innovation, and commercialization.


  • Open Access

    Digital transitions in healthcare: the need for transdisciplinary research to overcome barriers of privacy enhancing technologies uptake

    by Sarah van Drumpt, Tjerk Timan, Soukaina Talie, Thijs Veugen, Linda van de Burgwal

    Purpose: Adopting Privacy Enhancing Technologies (PETs) is key to accelerating digitisation of the healthcare sector while simultaneously upholding data protection rights and increasing cybersecurity. While such technologies are market-ready, the uptake of PETs in healthcare is lagging behind. In this study we explore how conflicting logics and disciplinary disparities impact PET adoption, and how transdisciplinary (TD) methods can facilitate collaboration and mutual learning to overcome these hurdles. Methods: A sequential mixed-methods case analysis is employed, focusing on a specific multidisciplinary partnership within the healthcare sector. TD methods are used to examine challenges and underlying value systems related to PET adoption. Results: Conflicting institutional logics in healthcare, driven by missions and value systems, hinder collaborative efforts. TD methods promote awareness of disciplinary disparities, fostering an appreciative attitude toward diverse viewpoints, with an active facilitator playing a crucial role. Mutual learning aids in identifying collective actions to address challenges but may lead to tensions when issues are framed differently. TD methods, however, fall short in guiding decision-making when preferences diverge. Conclusions: Sustainable PET adoption in healthcare requires addressing underlying value systems, effective communication, interdisciplinary consciousness and mutual learning. Acknowledging and managing tensions, particularly in diverse data governance contexts, proves important for successful PET adoption. Our research highlights the complexity of multidisciplinary partnerships, urging additional research to guide decision-making and governmental interventions. Ultimately, understanding these dynamics is a constructive approach for improving healthcare practices and outcomes through PET adoption.


  • Open Access

    A Case Study of European Collaboration between the Veterinary and Human Field for the Development of RSV Vaccines

    by Marga Janse, Giulia Sesa, Linda van de Burgwal

    The One Health (OH) approach describes the interconnection between the health of animals, humans, and the environment. The need for collaboration between the veterinary and human fields is increasing due to the rise in several infectious diseases that cross human–animal barriers and need to be addressed jointly. However, such collaboration is not evident in practice, especially for non-zoonotic diseases. A qualitative research approach was used to explore the barriers and enablers influencing collaborative efforts on the development of vaccines for the non-zoonotic RSV virus. It was found that in the European context, most veterinary and human health professionals involved in RSV vaccine development see themselves as belonging to two distinct groups, indicating a lack of a common goal for collaboration. Next to this, the different conceptualizations of the OH approach, and the fact that RSV is not a zoonotic disease, strengthens the opinion that there is no shared need for collaboration. This paper adds insights on how, for a non-zoonotic situation, collaboration between human and veterinary professionals shaped the development of vaccines in both areas; thus, improving public health requires awareness, mutual appreciation, and shared goal setting.


  • Open Access

    An elephant in the glasshouse? Trade-offs between acceleration and transformation in COVID-19 vaccine innovation policies

    by Linda van de Burgwal, Tom van der Valk, Hannes Kempter, Manuel Gadau, David Stubbs, Wouter Boon


  • Open Access

    Identifying Cross-Utilization of RSV Vaccine Inventions across the Human and Veterinary Field

    by Marga Janse, Swasti D. Soekhradj, Rineke de Jong, Linda H. M. van de Burgwal

    The respiratory syncytial virus (RSV) has two main variants with similar impact, a human and a bovine variant. The human respiratory syncytial virus (HRSV) is the most frequent cause of acute respiratory disease (pneumonia) in children, leading to hospitalization and causing premature death. In Europe, lower respiratory tract infections caused by HRSV are responsible for 42–45 percent of hospital admissions in children under two. Likewise, the bovine respiratory syncytial virus (BRSV) is a significant cause of acute viral broncho-pneumonia in calves. To date no licensed HRSV vaccine has been developed, despite the high burden of the disease. In contrast, BRSV vaccines have been on the market since the 1970s, but there is still an articulated unmet need for improved BRSV vaccines with greater efficacy. HRSV/BRSV vaccine development was chosen as a case to assess whether collaboration and knowledge-sharing between human and veterinary fields is taking place, benefiting the development of new vaccines in both fields. The genetic relatedness, comparable pathogeneses, and similar severity of the diseases suggests much can be gained by sharing knowledge and experiences between the human and veterinary fields. We analyzed patent data, as most of pharmaceutical inventions, such as the development of vaccines, are protected by patents. Our results show only little cross-utilization of inventions and no collaborations, as in shared IP as an exchange of knowledge. This suggests that, despite the similarities in the genetics and antigenicity of HRSV and BRSV, each fields follows its own process in developing new vaccines.


  • Darmbacteriën en ASS: een verkenning van de stand van zaken

    by Anne van der Geest, Annemarieke van Opstal, Saskia van Hemert, Linda van de Burgwal

    Th rough the gut-brain axis, there is communication between cognitive, emotional and behavioral brain centers on one side and the gut on the other. Disruption of the composition of gut bacteria can potentially cause the gut-brain axis to malfunction, leading to behavioral and gut problems linked to Autism Spectrum Disorders (ASD). Examples of interventions that potentially have an influence on the composition of gut bacteria include diet, poop transplants and probiotics. Th e restricted diet of patients with ASD may explain the disruption of the composition of gut bacteria. However, this does not appear to be a cause of ASD but the disturbance may be causing (worsening) of the symptoms. Another intervention that can aff ect the gut microbiota is a poop transplant. Improvement on several symptoms, such as social skills, hyperactivity, stereotyped behavior, and speech was observed, but the lack of a control group limits the validity of these results. A third type of intervention aimed at influencing the gut microbiota is probiotics. Although it is plausible that probiotics have an eff ect on ASD, this has not yet been scientifi cally established. This is because such research is inherently complex due to the large diversity of possible probiotics, the heterogeneity in the microbiota itself, external influences that are difficult to control, the range and heterogeneity in ASD symptoms, and the amount of factors that contribute to the development of ASD symptoms. In practice, it is difficult to establish “one size fi ts all” guidelines. Hence, working with an individualized approach that tailors interventions to each individual’s unique profile is recommended. For health care providers, this can be an opportunity to focus on what works in the specific situation of my patient.

  • To patent or not to patent? Consideration of the societal aspects of patenting across pharma-nutrition industries

    by Jelle J. Feddema, Mark B. van der Waal, Max J. Renes, Eric Claassen, Linda H.M. van de Burgwal


  • Open Access

    Barriers Influencing Vaccine Development Timelines, Identification, Causal Analysis, and Prioritization of Key Barriers by KOLs in General and Covid-19 Vaccine R&D

    by Marga Janse, Thomas Brouwers, Eric Claassen, Peter Hermans, Linda van de Burgwal

    A frequently mentioned factor holding back the introduction of new vaccines on the market are their prohibitively long development timelines. These hamper their potential societal benefit and impairs the ability to quickly respond to emerging new pathogens. This is especially worrisome since new pathogens are emerging at all-time high rates of over one per year, and many age-old pathogens are still not vaccine preventable.Through interviews with 20 key-opinion-leaders (KOLs), this study identified innovation barriers that increase vaccine development timelines. These innovation barriers were visualized, and their underlying causes revealed by means of qualitative root cause analysis. Based on a survey the innovation barriers were quantitatively ranked based on their relative impact on both regular, and Covid-19 vaccine development timelines. KOLs identified 20 key innovation barriers, and mapping these barriers onto the Vaccine Innovation Cycle model revealed that all phases of vaccine development were affected. Affected by most barriers is the area between the preclinical studies and the market entry. Difficult hand-off between academia and industry, lack of funding, and lack of knowledge of pathogen targets were often mentioned as causes. Quantitative survey responses from 93 KOLs showed that general vaccine development and Covid-19 vaccine development are impacted by distinct sets of innovation barriers. For the general vaccine development three barriers were perceived of the highest impact; limited ROI for vaccines addressing disease with limited market size, limited ROI for vaccines compared to non-vaccine projects, and academia not being able to progress beyond proof of principle. Of highest impact on Covid-19 vaccine development, are lack of knowledge concerning pathogen target, high risk of upscaling unlicensed vaccines, and proof of principle not meeting late-stage requirements. In conclusion, the current study demonstrates that barriers hampering timelines in vaccine development are present across the Vaccine Innovation Cycle. Prioritizing the impact of barriers in general, and in Covid-19 vaccine development, shows clear differences that can be used to inform policies to speed up development in both war and peace time.